FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia

Rhea-AI Summary

FibroBiologics (Nasdaq: FBLG) announced issuance of Canadian Patent No. 3118732 for “Treatment of Cachexia Using Fibroblast Cells and Products Thereof.” The patent covers composition and method claims for immune-modulating fibroblasts, stem-marker-expressing cells, and multiple dosing routes to address cachexia and related inflammation.

The filing highlights claims on marker-positive fibroblasts and methods to reduce inflammation and prevent or reverse weight loss in patients with cachexia; the company cites a cancer cachexia market projection of $3.2B by 2032.

Positive

• Issued Canadian Patent No. 3118732 covering fibroblast treatments for cachexia
• Claims include both composition and method protections for immune-modulating fibroblasts
• Patent specifies fibroblasts with distinct stem cell markers (SSEA3/4, Tra-1-60/81, Oct-4, CD markers)
• Cites a $3.2B projected cancer cachexia market by 2032, indicating commercial relevance

Negative

• Patent is limited to Canada, leaving other jurisdictions unprotected until further grants
• No new clinical efficacy or human trial results were disclosed to validate therapeutic benefit
• Company remains clinical-stage, so commercialization timelines and regulatory approvals are uncertain

Argus Feb 5 session

-9.20% close to close Open Argus

Details

News Market Reaction – FBLG

On Feb 5, the day this news came out, FBLG closed 9.20% below the previous close.

Data tracked by StockTitan Argus for the Feb 5 session.

Key Figures

Patent portfolio: 270+ patents issued and pending Cachexia cancer market: $3.2B Canadian patent number: 3118732

Patent portfolio

270+ patents issued and pending

Company-wide intellectual property

Cachexia cancer market

$3.2B

Projected market size by 2032

Canadian patent number

3118732

Issued by Canadian Intellectual Property Office

Historical Context

5 past events · Latest: Jan 20

5 events

1. Jan 20

   Conference presentation

   24h Move

   -3.7%

   Announcement of CEO presentation at DealFlow Discovery investor conference.

2. Jan 07

   Shareholder update

   24h Move

   +32.3%

   CEO letter detailing 2025 clinical, IP, manufacturing and financing milestones.

3. Jan 06

   Conference presentation

   24h Move

   +6.8%

   Notification of presentation at BFC Global Healthcare Business Development Conference.

4. Jan 05

   Preclinical results

   24h Move

   +1.5%

   Positive preclinical FSdC spheroid data in degenerative disc disease models.

5. Dec 31

   IND filing

   24h Move

   -7.0%

   IND submission to FDA for Phase 1/2 trial of CYPS317 in psoriasis.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

cachexia, c-reactive protein, interleukin-1, interleukin-6, +4 more

8 terms

cachexia medical

"Cachexia, a complex metabolic syndrome characterized by severe weight loss..."

Cachexia is a complex condition characterized by significant weight loss, muscle wasting, and weakness, often occurring in people with chronic illnesses such as cancer or severe infections. It reflects a state where the body is unable to maintain healthy tissue, leading to decline in overall strength and vitality. For investors, understanding cachexia is important because it can signal underlying health issues that may impact a company's performance, especially in industries related to healthcare and pharmaceuticals.

c-reactive protein medical

"...address the root cause of cachexia and associated inflammatory mediators such as C-reactive protein, Interleukin-1..."

C-reactive protein (CRP) is a blood biomarker that rises when the body has inflammation or infection, acting like a smoke detector that signals something is wrong. For investors, CRP matters because it is used in clinical tests and drug trials to show whether treatments reduce inflammation, can influence regulators’ and doctors’ decisions, and therefore affects the commercial prospects of diagnostics and therapeutic products.

interleukin-1 medical

"...inflammatory mediators such as C-reactive protein, Interleukin-1, Interleukin-6, and TNF-alpha."

A small signaling protein the immune system uses to start and amplify inflammation; think of it as an alarm bell that tells immune cells to respond to infection or injury. For investors, interleukin-1 matters because drugs that block or modify its activity are major targets for treating inflammatory diseases, so news about clinical results, approvals, or safety can sharply affect companies developing related therapies and their market value.

interleukin-6 medical

"...mediators such as C-reactive protein, Interleukin-1, Interleukin-6, and TNF-alpha."

Interleukin-6 is a small signaling protein the body releases to coordinate inflammation and immune responses, acting like a fire alarm that summons immune cells to sites of infection or tissue damage. It matters to investors because high or persistent levels are linked to disease activity and are a common drug target or clinical trial biomarker; changes in IL-6-related data can influence a therapy's approval prospects, market potential, and a company's valuation.

tnf-alpha medical

"...Interleukin-1, Interleukin-6, and TNF-alpha."

Tumor necrosis factor-alpha (TNF-alpha) is a small signaling protein the body uses to trigger and regulate inflammation, like a fire alarm that summons immune cells to a problem site. Investors watch it because elevated or controlled TNF-alpha levels are central to many inflammatory and autoimmune diseases, making it a common target for drugs and diagnostics; success or failure of therapies that block or measure TNF-alpha can greatly affect company value and market prospects.

intravenous medical

"Methods of treatment using fibroblasts to affected individuals via various routes, such as intravenous, subcutaneous..."

Intravenous means delivering a drug, fluid or substance directly into a vein so it goes straight into the bloodstream. For investors, that matters because intravenous products often act faster, require different manufacturing, regulatory steps and healthcare settings (like hospitals or clinics), and can affect pricing, adoption and revenue profiles in ways that differ from pills or topical treatments — like turning a slow-release delivery into a direct tap to the system.

subcutaneous medical

"Methods of treatment using fibroblasts to affected individuals via various routes, such as intravenous, subcutaneous, or intramuscular..."

Subcutaneous means situated or applied just beneath the skin. In finance, the term can describe processes or investments that are hidden or not immediately visible, much like something placed under the skin that isn't easily seen from the outside. Recognizing subcutaneous activities helps investors understand underlying factors that may influence markets or asset values over time.

intramuscular medical

"via various routes, such as intravenous, subcutaneous, or intramuscular, to ameliorate cachexia..."

A way of giving a medicine or vaccine by injecting it deep into a muscle, typically using a syringe and needle so the drug is absorbed into the bloodstream more steadily than a skin shot but faster than swallowing a pill. Investors care because this delivery method affects how quickly and reliably a treatment works, the type of manufacturing and packaging needed, clinical trial design and regulatory requirements, and patient or provider preferences that influence market uptake.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HOUSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the Canadian Intellectual Property Office has issued Canadian Patent No. 3118732, titled “Treatment of Cachexia Using Fibroblast Cells and Products Thereof.” This patent strengthens FibroBiologics’ intellectual property portfolio and underscores the Company’s commitment to advancing innovative therapies for debilitating conditions like cachexia.

Cachexia, a complex metabolic syndrome characterized by severe weight loss, muscle wasting, and inflammation, often accompanies chronic diseases such as cancer, HIV/AIDS, and chronic obstructive pulmonary disease. The cachexia market for cancer is projected to hit $3.2B by 2032. The newly issued patent covers methods and compositions for treating cachexia or related inflammation through the administration of fibroblasts, providing a novel approach to addressing this unmet medical need.

Key components of the patent include:

• The use of immune-modulating fibroblasts, which are cultured under specific conditions to enhance their ability to suppress inflammation and address the root cause of cachexia and associated inflammatory mediators such as C-reactive protein, Interleukin-1, Interleukin-6, and TNF-alpha.
• Composition of matter claims on fibroblasts that express detectable levels of specific stem cell markers, including SSEA3, SSEA4, Tra-1-60, Tra-1-81, Tra-2-54, Oct-4, CD13, CD44, CD49b, CD105, and aminopeptidase N, while not expressing detectable levels of SSEA1, enabling their potential to restore physiological, immunological, and metabolic homeostasis.
• Methods of treatment using fibroblasts to affected individuals via various routes, such as intravenous, subcutaneous, or intramuscular, to ameliorate cachexia, prevent weight loss, or increase weight in patients at risk for, or suffering from, the condition.
  
  

“We are thrilled with the issuance of this Canadian patent, which represents an important step forward in our pioneering work to leverage the regenerative and immunomodulatory properties of fibroblasts to combat cachexia, a condition that significantly impacts patient quality of life and outcomes in chronic diseases,” said Pete O’Heeron, Founder and Chief Executive Officer of FibroBiologics. “This milestone not only expands our global IP protection but also brings us closer to delivering transformative therapies that could change the standard of care for millions of patients worldwide.”

About FibroBiologics

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.

Cautionary Statement Regarding Forward-Looking Statements

This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning the scope and strength of the Company’s intellectual property portfolio, the potential indications for FibroBiologics’ programs, the potential clinical benefits of fibroblasts and fibroblast-derived materials in cachexia, and the potential cachexia market for cancer. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of FibroBiologics’ R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.

General Inquiries:
info@fibrobiologics.com

Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com

Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does FibroBiologics (FBLG) patent No. 3118732 cover for cachexia treatment?

It covers methods and compositions using fibroblast cells to treat cachexia and related inflammation. According to the company, claims include immune-modulating fibroblasts, specific stem-cell marker profiles, and various administration routes such as IV, subcutaneous, and intramuscular.

How significant is the Canadian patent for FBLG investors and market opportunity?

The patent strengthens FibroBiologics' intellectual property position in Canada for fibroblast-based cachexia therapies. According to the company, this complements its 270+ patents issued/pending and points to a cited cancer cachexia market projected at $3.2B by 2032.

Does the new patent from FibroBiologics (FBLG) guarantee a new treatment is available now?

No, the patent grants IP rights but does not imply an approved therapy is available. According to the company, it protects methods and compositions while clinical development and regulatory approvals remain necessary before commercialization.

Which biological markers are claimed in FibroBiologics' cachexia patent No. 3118732?

Claims specify fibroblasts expressing markers like SSEA3, SSEA4, Tra-1-60, Tra-1-81, Oct-4, CD13, CD44, CD49b, CD105, and aminopeptidase N. According to the company, these marker profiles differentiate therapeutic fibroblasts from non-therapeutic cells.

What next steps should investors expect after FibroBiologics (FBLG) received the Canadian patent?

Investors should expect continued clinical development and potential expansion of IP filings in other regions. According to the company, the patent expands global IP protection and supports ongoing efforts to advance fibroblast therapies toward clinical and regulatory milestones.